Dr. Reddy’s Laboratories launches Tadalafil Tablets USP in the U.S. Market

Published On: February 12th 2019 at 9:54 PM

Dr. Reddy's Laboratories LtdDr. Reddy’s Laboratories Ltd. along with its subsidiaries today announced the launch of Tadalafil Tablets USP, a therapeutic equivalent generic version of Adcirca (tadalafil) Tablets in the United States market, approved by the U.S. Food and Drug Administration (USFDA).

The Adcirca brand and generic had U.S. sales of approximately $490 million MAT for the most recent twelve months ending in November 2018 according to IMS Health*.

Dr. Reddy’s Tadalafil Tablets are available in 20 mg with 60 count bottle size.

Adcirca is a trademark of Eli Lilly and Company.

avatar
  Subscribe  
Notify of